• Transgene

  Led · Equity · Nov 2025

  Transgene focuses on the research and development of myvac, its platform of individualized therapeutic vaccines against cancer. The company is currently raising fresh capital to accelerate this program, planning to dedicate 70 % of the new proceeds to myvac’s clinical and technological advancement. Management states that the new cash will extend Transgene’s financial visibility through the beginning of 2028. Beyond myvac, Transgene continues to advance other oncology immunotherapies, though the article centers on the vaccine platform. The firm’s financing strategy includes both new cash and a debt-for-equity swap with a long-time shareholder, strengthening its balance sheet. No operating metrics such as revenue or patient numbers were disclosed in the press coverage.

• Keranova

  Led · Series A · Apr 2016

  Keranova develops instruments and an ultra-fast robotized laser for ophthalmic surgery, initially targeting cataract procedures. The company produced its first clinical prototype in Saint-Etienne leveraging research from two multidisciplinary teams at Jean Monnet University and holds innovations protected by 11 patent families. Its device treated its first patients in December 2018 and is positioned as an alternative to traditional phacoemulsification with the goal of precise, repeatable and automated procedures. Keranova aims to reduce manual intervention through automation and ultimately address refractory problems such as myopia and astigmatism at a later stage. Led by CEO and founder Fabrice Romano, the company intends to use recent funding to accelerate technology development and secure regulatory authorizations to market its solution. The articles report a €24M second financing completed in 2019. Keranova develops instruments for ophthalmic surgery, including a new surgical device that leverages joint multidisciplinary research at Jean Monnet University. The device is designed to substantially reduce manual intervention by increasing automation and precision, improving reproducibility and lowering operator-dependent clinical risk. The company plans to use recent funding to develop prototype surgical equipment and to complete a preclinical study required for filing for clinical trial approval. Keranova was founded in 2015 by Fabrice Romano (CEO) and is led operationally with Sophie Valla as managing director. The company recently completed a Series A round of €4m, providing capital to advance its prototype and regulatory program.

No current team members are available.